[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

871 Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Program: Oral and Poster Abstracts
Type: Oral
Session: 642. CLL: Therapy, excluding Transplantation: Novel Approaches to CLL Therapy
Tuesday, December 10, 2013: 7:30 AM
293-294 (Ernest N. Morial Convention Center)

Joseph M. M. Flynn, DO, MPH1, Leslie A. Andritsos, MD2, Jeffrey A. Jones, MD1, Amy J. Johnson, PhD3, Kami Maddocks, MD4*, Elizabeth Wiley5*, Karen Small, BSN6*, Eun Kyung Im, MD7*, Michael R. Grever, MD2, Rajat Bannerji, MD, PhD8*, John C. Byrd, MD9 and Honghong Zhou, PhD10*

1Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
2Division of Hematology, The Ohio State University, Columbus, OH
3Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
4Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
5The Ohio State University, Columbus, OH
6Merck & Co., Whitehouse Stations, NJ
7Merck, Whitehouse Stations, NJ
8Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
9Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
10Merck, Whitehouse Statioins, NJ

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults.  While the breadth of therapies for this incurable disorder has increased recently, patients afflicted with high risk disease have few and predominantly unsatisfactory options.  Cyclin-dependent kinase (CDKs) inhibitors, such as Flavopiridol, have demonstrated clinical activity in CLL, though have been associated with significant therapy associated tumor lysis (TLS).  Dinaciclib is a selective inhibitor of CDKs 1, 2, 5, and 9 that exhibits activity in CLL, including high risk subtypes.  

We performed a phase 1 dose escalation trial in relapsed and refractory CLL in order to determine the recommended phase 2 dose and maximum administered dose of dinaciclib.  Patients received treatment as a 2-hour IV infusion on days 1, 8 and 15 of a 28-day cycle.  The initial starting dose, determined based on preclinical data, was 5 mg/m2.  Other dosing cohorts of 7 mg/m2, 10 mg/m2, 14 mg/m2 and 17mg/m2 were included in the dose escalation schema.  An expansion cohort of patients utilizing an intra-patient dose escalation of 7mg/m2 on day 1, 10mg/m2 on day 8 and 14mg/m2 on day 15 during cycle 1 and 14mg/m2 on days 1, 8, and 15 of each subsequent cycle was further employed. Patients continued on treatment until there was disease progression, unacceptable toxicity or subject’s refusal to continue.

In total, 52 patients have been enrolled on this trial.  The median age is 62.4 years (range 43-79), with 46% of patients ≥65 years.  The majority of patients have advanced Rai stage (65%) and/or bulky disease (69%) and 46% with del(17p13.1).  The median number of prior therapies is 4 (range 1-12) with 92% having received prior fludarabine and 31% having received prior flavopiridol.  One episode of a dose limiting toxicity (DLT) was noted at 7mg/m2 (sepsis/death) and two at dose level of 17mg/m2 (hyperacute tumor lysis syndrome and pneumonia).  One further DLT of TLS occurred at the recommended phase II dose level of 14mg/m2 during cohort expansion for a total of 18 patients treated at 14mg/m2.  The most common serious adverse events included leucopenia, anemia, thrombocytopenia and metabolic evidence of tumor lysis, which occurred in 15% of patients.  Clinical response was assessed utilizing the 1996 NCI-WG CLL criteria.  The overall response rate of evaluable patients was 58% (28 of 48), while 57% patients with del(17p13.1) and 63% with del(11q22) achieved at least a partial response.  The median progression free survival was 481 days (95%  CI, 253 – 481).  For responders, the median treatment duration was 214.5 days (range, 79 – 470 days).

In conclusion, Dinaciclib is clinically active in this population of relapsed and refractory CLL.  Importantly, patients with high risk disease, such as del(17p13.1) demonstrated impressive overall responses.  Utilizing a dose escalation treatment model, Dinaciclib is well tolerated, safe and associated with typical toxicities which are readily managed.  The use of this agent in combination with other efficacious agents, especially in the high risk CLL population is warranted.

Disclosures: Jones: Pharmacyclics: Membership on an entity’s Board of Directors or advisory committees , Research Funding . Small: Merck: Employment . Im: Merck: Employment . Zhou: Merck: Employment .

Previous Abstract | Next Abstract >>

*signifies non-member of ASH